Title: Current target ranges of mycophenolic acid exposure and drug-related adverse events: A 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients
Authors: Kuypers, Dirk ×
de Jonge, Hylke
Naesens, Maarten
de Loor, Henriette
Halewijck, Evelyne
Dekens, Marc
Vanrenterghem, Yves #
Issue Date: Apr-2008
Publisher: Elsevier
Series Title: Clinical therapeutics vol:30 issue:4 pages:673-683
Abstract: Background: Two recent randomized clinical trials-Fixed Dose Versus Concentration Controlled and the Apomygre-evaluating the benefit of therapeutic drug monitoring of mycophenolate mofetil (MMF) in renal allograft recipients reported conflicting results. In both studies, target mycophenolic acid (MPA) AUC(0-12h) ranges (le, values used to guide MMF dosing) were derived from a previous study establishing target MPA AUC(0-12h) ranges in cyclosporine-treated patients between 30 and 60 mg/L . h(-1). Both studies found an association between MPA exposure and acute rejection. However, only one of the studies found concentration-controlled MMF dosing to be significantly associated with less biopsy-proven acute-rejection episodes compared with fixed dosing. No reduced incidence of MMF-related adverse events (AEs) was observed in either of the 2 trials when MMF concentration-controlled and fixed dosing were compared.
ISSN: 0149-2918
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Nephrology
Department of Microbiology & Immunology - miscellaneous
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science